Magnesium threonate vs bisglycinate: sleep, brain and recovery

Magnesium threonate vs bisglycinate: human evidence on sleep, cognition and recovery, with study doses, safety, EU rules and a critical comparison.

Two unlabelled glass dishes of white powder on a dark laboratory work surface
Comparing magnesium forms: a symbolic editorial illustration. Powder appearance identifies neither chemical form nor purity.AI-generated illustration.

Six weeks, one hundred adults and an eye-catching number: in a randomised trial published in 2026, people taking magnesium L-threonate improved more than the placebo group on a composite cognitive test. The researchers also converted test performance into an estimated “brain age”, reporting a 7.5-year advantage. This was not measured biological rejuvenation. And although every participant was dissatisfied with their sleep, several sleep outcomes showed no significant difference between groups. Lopresti and Smith, 2026

That combination makes the comparison interesting. Does threonate belong in the brain category, while bisglycinate is the option for sleep and exercise recovery? Or does marketing draw a clearer dividing line than the research supports?

The short answer

Neither magnesium threonate nor bisglycinate is a proven overall winner. L-threonate has preliminary positive human findings on selected cognitive tests. A larger bisglycinate sleep trial found a small improvement in subjective insomnia symptoms. Published evidence does not establish reliably better objective sleep, faster recovery or superiority in a direct comparison. A relevant head-to-head trial is recruiting, with no results yet. Schuster et al., 2025, Sleep review, 2026, UCLA trial registry

Research checked on 2 November 2026. Amounts below describe research interventions, not general instructions for supplementation.

Why getting enough magnesium matters in the first place

Magnesium is essential. It supports enzymes and binds ATP, the molecule that supplies immediately usable energy in cells. These roles help normal energy metabolism and contribute to muscle contraction, nerve signalling and the regulation of heart rhythm. They matter regardless of which magnesium compound supplies the mineral. DGE: biological functions

Low intake is not a diagnosis of deficiency

Inadequate magnesium status can initially go unnoticed. A pronounced deficiency can cause muscle cramps, tingling and abnormal heart rhythms, among other problems; potassium and calcium balance may also be affected. These symptoms have many possible causes. Treating a deficiency helps prevent its consequences, which is why persistent symptoms deserve medical assessment. gesund.bund.de

Intake, nutritional status and a clinical diagnosis are different things. An estimated intake below a reference value first signals a possible nutritional gap. It does not establish clinical deficiency. Conversely, a serum measurement only incompletely reflects magnesium stores, most of which are outside the bloodstream. Assessment brings together diet, illnesses, medicines and laboratory findings. NIH: assessing magnesium status

German dietary data illustrate the distinction. The National Nutrition Survey II collected data between 2005 and 2007 from German-speaking people aged 14 to 80. Its report found that 26% of men and 29% of women consumed less magnesium than the recommendations used at the time. Those are proportions below historical intake recommendations, not laboratory-confirmed deficiencies. The older survey and reference values cannot establish the prevalence of deficiency in Germany in 2026 or identify an individual’s need for a supplement. MRI: survey design, Original report, section 5.7.4

When additional magnesium can offer a real benefit

For a medically diagnosed deficiency, replacing missing magnesium can correct the shortfall and improve symptoms caused by it. Depending on the cause and severity, dietary changes or oral preparations may suffice; severe cases may require medically supervised intravenous treatment. gesund.bund.de: treatment

Targeted supplementation can also be useful after individual assessment when food consistently fails to provide enough. Poor appetite, chewing or swallowing difficulties, illnesses and medicines can make adequate nutrition harder to achieve. Age alone does not justify routine supplementation. The relevant questions are which gap actually exists and how best to address it. BfR: benefits and risks in older age

Food as the foundation, supplementation with a clear purpose

Whole grains, pulses, nuts, seeds and green vegetables supply magnesium; magnesium-rich mineral water also contributes. Oats with nuts, a bean dish or wholegrain bread with vegetables can all fit into everyday meals. Healthy kidneys normally excrete excess magnesium from ordinary foods. DGE: food sources and intake

Preparations can address a specific gap but add doses and risks. Alongside gastrointestinal symptoms, severe overdosing can cause dangerous blood pressure, breathing and heart problems, particularly with impaired kidney function. Medicine interactions also matter. NIH: health risks

The practical question is: What benefit is supported for my starting situation, and what additional burden comes with it? Meeting requirements and treating deficiency-related symptoms are important goals. Whether extra magnesium also improves sleep, memory or training performance must be established in the relevant human trials. The mineral’s essential role does not establish the superiority of an expensive compound.

Nutrition section added: sources checked on 3 November 2026.

Two compounds, the same mineral

Supplements contain magnesium as a compound. L-threonate is the salt of L-threonic acid, which occurs in vitamin C metabolism. It is different from the amino acid threonine. Bisglycinate binds magnesium to two glycine units; glycine is an amino acid. Labels often shorten the name to “glycinate”. The ingredient list matters when identifying the actual compound and any added ingredients. EFSA, 2024, Schuster et al., 2025

These partners affect properties such as solubility and the proportion of magnesium by mass. They do not assign each compound an exclusive job. Once swallowed, absorption, distribution and the body’s regulation of magnesium all matter. Binding a mineral to glycine does not automatically turn it into a sleep treatment; pairing it with threonate does not automatically make it a memory enhancer.

Elemental magnesium: the number that changes the comparison

“2,000 mg magnesium L-threonate” does not mean “2,000 mg magnesium”. Elemental magnesium means the mass of the mineral within the compound, not metallic magnesium for swallowing. The 2026 trial supplied 145 mg magnesium from 2,000 mg of its L-threonate preparation each day. EU specifications give a magnesium content of 7.2–8.3% for the authorised ingredient. The actual product declaration remains important. 2026 trial, EU Union list

  • L-threonate trial, 2026

    2000 mg study preparation per day

    containing 145 mg magnesium = 7.25%

  • Bisglycinate trial, 2025

    1786 mg magnesium bisglycinate per day

    containing 250 mg magnesium ≈ 14.0%

Composition of the tested preparations, not absorption percentages or a comparison of effectiveness. Capsule shells and other excipients are not shown.

Calculated from the original reports: 145/2000 and 250/(2 × 893). The daily regimens contained different amounts of magnesium. Lopresti and Smith, 2026; Schuster et al., 2025.

Bioavailability is not a shortcut to clinical benefit

Bioavailability concerns how much of a substance is absorbed and becomes available to the body. Magnesium studies may examine changes in blood or urine for this purpose. Those measurements address a different question from a memory task or a refreshing night’s sleep. A higher blood measurement does not demonstrate a higher magnesium concentration in the human brain. NIH fact sheet

A randomised crossover study in 40 adults illustrates the limits of absorption rankings. It compared a microencapsulated preparation with other sources, including bisglycinate, but not L-threonate. The study measured responses to a single dose, not long-term sleep or recovery. It was industry funded. A short experiment of this kind cannot establish one universally “best absorbed” form for every person and purpose. Absorption trial, 2024

Where did “brain magnesium” come from?

The phrase has a scientific starting point. In 2010, researchers reported that magnesium L-threonate raised brain magnesium in rats, alongside changes in learning performance and synapses. Synapses are the junctions through which nerve cells communicate. This made an interesting hypothesis testable. It remained an animal experiment. Slutsky et al., 2010

The blood–brain barrier regulates exchange between the circulation and the brain. Changing brain magnesium in an animal model does not establish a particular clinical effect in people, let alone an advantage over bisglycinate. That question needs comparable human interventions. “Brain magnesium” is not a medical drug class and does not mean other magnesium sources fail to supply the nervous system.

EFSA’s assessment helps separate the questions. It regards magnesium from L-threonate as bioavailable and considers the ingredient safe under specified conditions. It does not certify superior memory benefits. Absorption, safety and effectiveness are distinct assessments. EFSA, 2024

What people actually achieved on cognitive tests

An early double-blind trial followed adults aged 50–70 with cognitive complaints for twelve weeks; 44 completed it. A composite cognitive score improved more with the L-threonate-containing preparation MMFS-01 than with placebo. This was an encouraging finding in a small, selected population. It established neither dementia prevention nor a general benefit for healthy young adults. Neurocentria funded the trial and contributed to design, cognitive analyses and the manuscript. Liu et al., 2016

The 2026 trial recruited a younger population: 100 adults aged 18–45 who reported unsatisfactory sleep, assigned to six weeks of L-threonate or placebo. The NIH Total Cognition Composite, a combined score from standardised tasks, favoured L-threonate for change over time (p = 0.043). Raven’s matrices, a separate test of reasoning, showed no between-group difference (p = 0.953). Lopresti and Smith, 2026

A p-value describes how unusual the data would be under a statistical null hypothesis. It is not the probability that a supplement “works”, and it does not tell us whether an improvement is large enough to notice in everyday life. When researchers examine numerous outcomes, isolated positive results need particularly careful interpretation.

The younger-brain headline came from a model linking test performance to age. It did not show brain tissue or biological ageing being reversed by 7.5 years. Threotech funded the study, supplied the product and contributed to study design; the authors work for a contract research organisation. These interests do not automatically invalidate the results, but independent replication matters. An October 2026 correction clarifies that the statistical tests were two-sided. The authors state that the reported results and p-values are unchanged. Original paper, Correction

A further 2022 study in 109 adults reported better memory-test scores after 30 days. However, the intervention combined L-threonate with phosphatidylserine and vitamins C and D. Its result cannot be attributed to L-threonate alone. The authors declared no known relevant competing interests. Zhang et al., 2022

Observational data cannot replace these experiments. A 2024 systematic review identified three RCTs and twelve cohort studies. The small RCT evidence base was insufficient to establish effects of supplements; associations between magnesium status and later cognition did not demonstrate a treatment benefit. The review predates the new 2026 trial and cannot settle the current formulation question either. Chen et al., 2024

Hands at a keyboard and response button in a quiet research room, with an unreadable out-of-focus screen
A symbolic testing scene. Computer tasks measure selected abilities; estimated cognitive age is not a measure of biological rejuvenation. AI-generated illustration.

Sleep: feeling better and sleeping longer are different outcomes

Feeling less exhausted in the morning can matter. Still, three questions should remain separate: how people rate their sleep, how sleep problems affect their day, and what overnight measurements show about duration, waking or sleep stages.

Bisglycinate: a small questionnaire advantage

In 2025, 155 adults reporting poor sleep were randomised for four weeks. The active group received 250 mg elemental magnesium daily as bisglycinate. Their Insomnia Severity Index (ISI), a questionnaire covering the severity and consequences of sleep problems, fell by 3.9 points, compared with 2.3 under placebo. The additional average reduction was approximately 1.6 points. The effect was small (Cohen’s d = 0.2; p = 0.049). Schuster et al., 2025

Other psychological outcomes did not differ significantly between groups. There were no objective sleep measurements. The full text reports institutional funding from Leibniz University Hannover; Biogena manufactured the study product. Co-author Lopresti disclosed involvement in nutraceutical contract research and presentation honoraria.

The preparation also provided approximately 1.5 g glycine per day. Without a glycine-only comparison arm, the separate contributions of mineral and ligand cannot be identified. Small studies using glycine alone, often at 3 g, cannot simply be applied to a bisglycinate capsule. An exploratory analysis suggesting larger improvements in people with lower dietary magnesium intake also remains uncertain: the dietary questionnaire was not validated, and magnesium deficiency was not established biochemically. Trial full text, Glycine trial, 2012

L-threonate: promising signals alongside several null findings

A 2024 study randomised 80 adults aged 35–55 to 1 g L-threonate daily or placebo for 21 days. Selected questionnaire domains and Oura-derived scores favoured the intervention. Actual total sleep time and sleep efficiency did not show a corresponding significant interaction effect. A “Deep Sleep Score” is also different from extra deep-sleep minutes measured in a sleep laboratory. Hausenblas et al., 2024

A correction published in 2025 adds two important limitations: the trial was registered retrospectively, and AIDP commissioned and funded it and owns patents. Three authors received payments from AIDP. The original competing-interest declaration was incomplete. 2025 correction

In the six-week 2026 trial, self-reported sleep-related daytime impairment improved more with L-threonate. General sleep disturbance, restorative sleep and several ring-derived measures—including sleep duration, efficiency and estimated stages—did not show significant between-group differences. A lower overnight heart rate or changed heart rate variability is an interesting accompanying observation, not proof of improved muscle recovery. Lopresti and Smith, 2026

A quiet dark bedroom with a bed and a hand wearing an unbranded tracking ring, with no visible face
Symbolic sleep tracking scene, not a photograph of a trial. A ring estimates sleep patterns; it does not replace a sleep-laboratory assessment. AI-generated illustration.

What does the whole evidence base say?

The systematic review published in August 2026 included twelve RCTs addressing sleep or insomnia and three separately analysed trials concerning movement- or cramp-related sleep disturbance. Participants, preparations, doses and measurement methods differed substantially. The authors rated the certainty of evidence low to very low and did not support oral magnesium as a routine insomnia treatment. Searches ran to 1 June 2026. Several review authors also contributed to studies discussed here; a review does not create an independent new group of participants. Lopresti et al., 2026

Persistent difficulty falling or staying asleep therefore warrants attention to the cause. For chronic insomnia, cognitive behavioural therapy for insomnia is the first-line treatment. It addresses sleep behaviours and sleep-related thoughts, among other factors. European insomnia guideline, 2023

Muscles and recovery: adequate intake or extra performance?

Magnesium participates in energy metabolism and muscle function. A nutrient being necessary does not mean extra amounts improve an already adequate supply. It is the same mistake as assuming that because an engine needs oil, more oil will always make it faster. NIH fact sheet

A small double-blind study in 22 young adults examined ten days of 350 mg magnesium daily and a bench-press protocol designed to induce soreness. Some ratings of soreness and perceived recovery were more favourable, while performance findings were less clear. The amount exceeded the European upper level for supplemental magnesium. This describes a research intervention, not a recommended dose. Reno et al., 2022

A 2024 systematic review found only four eligible studies examining soreness under different exercise conditions. It provides clues, not a robust ranking of magnesium forms or evidence of greater long-term muscle growth. Perceived recovery, inflammatory markers and training performance are different outcomes. 2024 review

The practical sequence is straightforward: examine nutrition, training load and sleep conditions, then establish whether supplementation addresses a specific need. The article on progressive overload explains how to build training demands sensibly. The quercetin evidence review shows why a favourable laboratory marker is not automatically a recovery benefit.

A practical comparison

Magnesium L-threonate and bisglycinate: evidence by goal
Goal or questionMagnesium L-threonateMagnesium bisglycinateWhat the evidence supports
Cognitive performancePositive signals in small human trials, alongside neutral testsNo similarly persuasive form-specific cognitive evidence found in the searchThreonate has been studied more; superiority remains unresolved
Subjective sleepSome positive domains, others neutralSmall ISI advantage after four weeksPreliminary findings, not a reliable effect
Objective sleepInconsistent wearable findingsMain trial did not measure objective sleepNo dependable winner
Muscles and recoveryNo convincing form-specific advantage establishedSmall magnesium/glycinate findings, no direct superiority evidenceSeparate adequate intake from additional benefit
Elemental magnesiumLow proportion by mass; 145 mg from 2 g in the RCT250 mg from 1786 mg in the sleep RCTCompare the mineral and the preparation separately
TolerabilityShort trials do not establish long-term safetyGenerally well tolerated in the sleep RCTNo established universal gastrointestinal advantage
Head-to-head evidenceUCLA trial recruitingIncluded in the same trialNo results yet

This table summarises the linked studies; it is not a direct experiment comparing the compounds. Declaring “threonate wins for cognition, bisglycinate wins for sleep” skips differences in participants, doses and measurements.

Which amounts were actually studied?

For reference: the 2026 L-threonate trial used 2 g preparation supplying 145 mg magnesium daily for six weeks; the 2024 trial used 1 g preparation daily for 21 days; the 2025 bisglycinate trial used 250 mg magnesium daily for four weeks. These are not equivalent doses or a basis for combining products. Nor do they establish an optimal time of day to take magnesium. 2026 RCT, 2024 RCT, 2025 RCT

The German Nutrition Society gives estimated adequate total intakes of 350 mg daily for adult men and 300 mg for adult women. These are not supplement doses. Whole grains, pulses, nuts and seeds contribute to intake. Germany’s BfR proposes a maximum of 250 mg magnesium per supplement’s recommended daily serving, divided into at least two portions. This proposal is neither an individual assessment of need nor a generally binding statutory supplement limit. DGE, BfR

Tolerability, interactions and important risks

Supplemental magnesium can cause diarrhoea, nausea and abdominal cramps. Dose, accompanying ingredients and individual circumstances matter. Short-term tolerability observations do not guarantee years of safe use. Impaired kidney function can reduce magnesium excretion, increasing the risk of dangerously high levels. Magnesium-containing laxatives and antacids contribute to the overall exposure. NIH

Magnesium can reduce absorption of some medicines, particularly tetracycline and quinolone antibiotics and oral bisphosphonates. Required intervals depend on the medicine and its prescribing information; a pharmacist or treating clinician can clarify them. Some diuretics and long-term proton pump inhibitor use can themselves alter magnesium status. NIH

Poor sleep alone does not diagnose magnesium deficiency. Equally, a single normal serum measurement cannot exclude every inadequate supply: only a small fraction of body magnesium circulates in blood. Symptoms, diet, medicines and any further investigations need to be interpreted together. A nonspecific symptom is not a reason to keep increasing a dose. NIH

L-threonate in the EU: authorisation and efficacy claims are separate

Four regulatory questions should be distinguished. Novel-food authorisation under Regulation (EU) 2024/2694 permits the specified ingredient in adult food supplements, excluding pregnant and breastfeeding women; labelling must communicate this restriction. The current Union list sets a maximum of 250 mg magnesium per day from this source. Corrigendum 2024/90741 explicitly clarifies that the limit refers to Mg, not 250 mg of the whole compound. Union list, consolidated version of 10 August 2026, Corrigendum

EFSA assessed 3 g of the ingredient supplying up to 250 mg magnesium. This was an assessed ingredient amount under defined conditions, not general consumption advice. Separately, Regulation (EU) 2025/2225 added L-threonate to the permitted magnesium sources in the food supplements directive. EFSA, Regulation 2025/2225

The authorisation grants data protection to AIDP until 7 November 2029. It protects specific application data; subsequent authorisations without reliance on those data or with consent remain possible. This is not an efficacy endorsement or a statement that only one consumer brand may legally exist. Regulation 2024/2694, Articles 2–3

Finally, health claims have their own rules. Authorised statements concerning normal muscle or nervous-system function apply to magnesium subject to their conditions. They do not create authorised promises about “brain rejuvenation”, insomnia treatment or threonate’s superiority. A positive clinical paper does not automatically expand permitted marketing claims. EU Regulation 432/2012

What the next study needs to resolve

UCLA trial NCT07640685 compares glycinate, L-threonate and placebo in collegiate athletes. Its registry reports recruitment from October 2026, with no results at the research cutoff. The declared elemental magnesium doses also differ between arms. Any future difference would initially compare the tested regimens, not automatically establish an intrinsic chemical advantage. ClinicalTrials.gov

For now, the fair answer is more precise than a winner’s label. Threonate offers interesting cognitive leads; bisglycinate offers a small subjective sleep finding. The striking younger-brain number remains a model estimate, while many overnight measurements are less exciting. The important next step is independent, larger research confirming benefits that matter in daily life, with clear primary outcomes, comparable doses and sufficiently long follow-up.

For readers, that means clarifying the goal and nutritional situation before judging the compound. Both forms deserve scientific interest. Current evidence does not justify assigning them fixed roles or declaring an overall winner.

Quick answers

Frequently asked questions about threonate and bisglycinate

Which magnesium is better for sleep: glycinate or threonate?

There is no established winner. Bisglycinate showed a small subjective insomnia benefit; L-threonate produced some positive and some neutral sleep findings. Good direct outcome data are still missing.

Is magnesium L-threonate the best magnesium for the brain?

Small human trials provide positive signals on selected tests. They establish neither general superiority nor biological rejuvenation or proven dementia prevention.

What does elemental magnesium mean?

It is the actual mass of the mineral within a compound. In the 2026 RCT, 2000 mg of the L-threonate preparation supplied 145 mg magnesium daily; the remaining mass was not additional magnesium.

Is magnesium bisglycinate better for recovery?

A form-specific advantage over L-threonate has not been demonstrated. Small magnesium and soreness trials are interesting, but do not establish greater muscle growth or faster recovery in general.

Can magnesium L-threonate be sold in the EU?

The specified ingredient is authorised under conditions: adult supplements, excluding pregnancy and breastfeeding, with no more than 250 mg magnesium daily from this source. Data protection and health claims are separate requirements.

Can threonate and bisglycinate be combined?

An additional benefit of the combination is not established. Elemental amounts and other magnesium-containing products add together. Kidney disease and medicines make medical or pharmaceutical clarification particularly important.

Transparency

Sources and references

  1. The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adults: a randomised, double-blind, placebo-controlled trialLopresti and Smith, Frontiers in Nutrition (2026); PMID 41601871doi.orgaccessed 02/11/2026
  2. Correction: The effects of magnesium L-threonate (Magtein®) on cognitive performance and sleep quality in adultsLopresti and Smith, Frontiers in Nutrition (15 October 2026)doi.orgaccessed 02/11/2026
  3. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled TrialSchuster, Cycelskij, Lopresti and Hahn, Nature and Science of Sleep (2025); DOI 10.2147/NSS.S524348pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  4. Magnesium Supplementation for Sleep in Adults: A Systematic Review of Randomized Controlled TrialsLopresti, Smith and Drummond, Journal of Dietary Supplements (2026); DOI 10.1080/19390211.2026.2719670pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  5. Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trialHausenblas et al., Sleep Medicine: X (2024); DOI 10.1016/j.sleepx.2024.100121pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  6. Corrigendum/Erratum to Magnesium-L-threonate improves sleep quality and daytime functioningHausenblas et al., Sleep Medicine: X (2025); PMID 40567408doi.orgaccessed 02/11/2026
  7. Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled TrialLiu et al., Journal of Alzheimer’s Disease (2016); DOI 10.3233/JAD-150538pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  8. Enhancement of learning and memory by elevating brain magnesiumSlutsky et al., Neuron (2010); DOI 10.1016/j.neuron.2009.12.026pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  9. Comparative Clinical Study on Magnesium Absorption and Side Effects After Oral Intake of Microencapsulated Magnesium (MAGSHAPE Microcapsules) Versus Other Magnesium SourcesPajuelo et al., Nutrients (2024); DOI 10.3390/nu16244367pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  10. Effects of Magnesium Supplementation on Muscle Soreness and PerformanceReno et al., Journal of Strength and Conditioning Research (2022); DOI 10.1519/JSC.0000000000003827pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  11. Effects of magnesium supplementation on muscle soreness in different type of physical activities: a systematic reviewTarsitano et al., Journal of Translational Medicine (2024)doi.orgaccessed 02/11/2026
  12. The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteersBannai et al., Frontiers in Neurology (2012); DOI 10.3389/fneur.2012.00061pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  13. The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023Riemann et al., Journal of Sleep Research (2023)doi.orgaccessed 02/11/2026
  14. Safety of magnesium L-threonate as a novel food and bioavailability of magnesium from this sourceEFSA NDA Panel (2024); full text PMC10934248doi.orgaccessed 02/11/2026
  15. Commission Implementing Regulation (EU) 2024/2694European Commission (2024), authorisation and protected dataeur-lex.europa.euaccessed 02/11/2026
  16. Union list of novel foods: Regulation (EU) 2017/2470, consolidated version 10 August 2026EUR-Lex; CELEX 02017R2470-20260810eur-lex.europa.euaccessed 02/11/2026
  17. Corrigendum 2024/90741: maximum levels of MgOfficial Journal of the EU (18 November 2024)eur-lex.europa.euaccessed 02/11/2026
  18. Commission Regulation (EU) 2025/2225: magnesium L-threonate as a magnesium sourceEuropean Commission (2025)eur-lex.europa.euaccessed 02/11/2026
  19. Commission Regulation (EU) No 432/2012: permitted health claimsEuropean Commission, Annex: magnesiumeur-lex.europa.euaccessed 02/11/2026
  20. Höchstmengenvorschläge für Magnesium in Lebensmitteln inklusive NahrungsergänzungsmittelnBundesinstitut für Risikobewertungbfr.bund.deaccessed 02/11/2026
  21. Magnesium: ReferenzwerteDeutsche Gesellschaft für Ernährungdge.deaccessed 02/11/2026
  22. Magnesium — Health Professional Fact SheetUS National Institutes of Health, Office of Dietary Supplementsods.od.nih.govaccessed 02/11/2026
  23. UCLA Magnesium Formulation Athlete Study (NCT07640685)ClinicalTrials.gov; recruiting; update posted 15 October 2026; no resultsclinicaltrials.govaccessed 02/11/2026
  24. A Magtein®, Magnesium L-Threonate, -Based Formula Improves Brain Cognitive Functions in Healthy Chinese AdultsZhang et al., Nutrients (2022); DOI 10.3390/nu14245235pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  25. Magnesium and Cognitive Health in Adults: A Systematic Review and Meta-AnalysisChen et al., Advances in Nutrition (2024); DOI 10.1016/j.advnut.2024.100272pubmed.ncbi.nlm.nih.govaccessed 02/11/2026
  26. Ausgewählte Fragen und Antworten zu MagnesiumDeutsche Gesellschaft für Ernährungdge.deaccessed 03/11/2026
  27. Nutzen und Risiken von Mikronährstoffsupplementen im AlterBundesinstitut für Risikobewertungbfr.bund.deaccessed 03/11/2026
  28. Magnesiummangel — Vorbeugung und Behandlunggesund.bund.de, Bundesministerium für Gesundheitgesund.bund.deaccessed 03/11/2026
  29. Die Nationale Verzehrsstudie II — Studiendesign und ErhebungszeitraumMax Rubner-Institutmri.bund.deaccessed 03/11/2026
  30. Nationale Verzehrsstudie II, Ergebnisbericht Teil 2: Abschnitt 5.7.4 MagnesiumMax Rubner-Institut (2008), S. 133–134; damalige D-A-CH-Referenzwertemri.bund.deaccessed 03/11/2026

How sources, boundaries and article status are presented